Intellia Therapeutics' (NTLA) Buy Rating Reaffirmed at HC Wainwright

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright's target price indicates a potential upside of 261.01% from the stock's previous close.

NTLA has been the subject of several other reports. Chardan Capital reissued a "buy" rating and set a $68.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 9th. Wedbush restated a "neutral" rating and set a $7.00 price target (down from $10.00) on shares of Intellia Therapeutics in a report on Thursday, May 29th. Canaccord Genuity Group lowered their target price on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a research note on Tuesday, June 3rd. Guggenheim reduced their price objective on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Finally, The Goldman Sachs Group reissued a "sell" rating and issued a $9.00 price target on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.95.

Intellia Therapeutics Trading Down 0.5%

Shares of NASDAQ:NTLA opened at $8.31 on Monday. The company has a 50 day moving average of $8.09 and a 200-day moving average of $9.79. The firm has a market cap of $860.77 million, a P/E ratio of -1.53 and a beta of 2.14. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. The firm had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. The business's revenue for the quarter was down 42.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.12) earnings per share. Equities research analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

Several large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in Intellia Therapeutics in the 4th quarter valued at $25,000. Northwestern Mutual Wealth Management Co. grew its holdings in Intellia Therapeutics by 56.4% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock worth $33,000 after acquiring an additional 1,655 shares during the last quarter. Sterling Capital Management LLC increased its position in Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock valued at $37,000 after acquiring an additional 2,867 shares in the last quarter. Harbour Investments Inc. raised its stake in shares of Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after acquiring an additional 2,264 shares during the last quarter. Finally, Whipplewood Advisors LLC acquired a new position in shares of Intellia Therapeutics during the fourth quarter worth approximately $40,000. Institutional investors own 88.77% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.